With a deep passion for public health and evidence-based decision-making, I bring a unique blend of legal, scientific, and medical expertise to the field of drug regulation. My work has been instrumental in shaping the regulation of psychiatric applications for psychedelics such as MDMA and psilocybin in Australia, where I have served as a lead legal, scientific, and medical writer.

At the heart of my work is a commitment to driving meaningful change in therapeutic goods regulation. I actively advocate for amendments to Australian Federal therapeutic laws, using my regulatory expertise to enhance public health outcomes, improve patient access, and promote safety in healthcare.

Beyond policy and regulation, I remain deeply engaged in clinical and academic research, focusing on pharmaceuticals, medical foods, and therapeutic goods. My goal is to bridge the gap between groundbreaking scientific advancements and the regulatory frameworks that govern them — ensuring that innovation translates into real-world benefits for patients and practitioners alike.